Abstract:
The present invention refers to the EMID2 protein or a nucleic acid coding thereof for use for the treatment of a tumor or for the treatment or prevention of metastasis. Compositions, vectors and formulations for the administration of EMID2 or a nucleic acid coding thereof for the above mentioned uses are also within the scope of the invention.
Abstract:
Method to carry out analyses on a sputum sample (11) comprising at least one component (C i ), that provides the following steps: - making available said sputum sample (11); - making available at least one set of reference data (14) associated with different microbial-based pulmonary pathological conditions; - measuring at least a relaxation time of the hydrogen atoms (T 2i ) and an average relaxation time of the hydrogen atoms (T 2m ); - comparing said average relaxation time (T 2m ) and said relaxation times of the hydrogen atoms (T 2i ) with said reference data (14) in order to determine the pathological condition associated with said sputum sample (11); - supplying information (17) correlated to the pathological condition associated with said sputum sample (11) and/or correlated to at least part of said components (C i ).
Abstract:
It is described the influence of the presence of mutations in the TP53 gene in association with high levels of the enzyme prolyl isomerase Pin1 and a molecular signature of 10 genes expression correlated with the expression of Pin1 and p53 for the prognosis of breast tumors. The association between overexpression of Pin1 and the presence of protein p53 mutants induces transcriptional programs which promote tumor aggressiveness and in a cohort of patients the overexpression of Pin1 has proved to influence the prognostic value of the presence of mutations in the gene TP53. The assessment of the expression of Pin1 in the presence of mutations of the gene TP53, together with the detection of the expression of the genes forming the molecular signature can therefore be used for the prognosis of breast cancer.
Abstract:
The present invention concerns a method for the identification of specific compounds which modulate brain-derived neurotrophic factor, which can be used as drugs for the treatment of neurological and neuropsychiatric diseases and which are suitable for the treatment of deleterious effects caused to the nervous system by abuse of illegal or legal drugs.
Abstract:
The invention relates to a dimethylsulphoxide and limonene based paint stripping composition, preferably thickened by adding a thickener of cellulose type, and to a device for its application, formed from an absorbent layer in which the composition is included and a support layer. The device is suitable for a method of paint stripping by peeling.